



Press release, December 2, 2014

Publication of change in the total number of shares and votes in Diamyd Medical AB

As of December 2, 2014, the share capital in Diamyd Medical AB (publ) is 2,010,142.3 SEK. The total number of votes is 2,844,668 and the total number of shares is 19,819,422, divided among 958,584 shares of series A (1 vote) and 18,860,838 shares of series B (1/10 vote).

The change is, as previously announced, due to a direct placement of 100,000 new series B shares to Protein Sciences Corporation, Inc., due to a signed agreement. The Board of Diamyd Medical decided on the new issue based on the authorization given by the Annual General Meeting on November 22, 2013.

About Diamyd Medical

Diamyd Medical is dedicated to fighting type 1 diabetes and to working toward a cure for the disease. Diamyd Medical's projects include development of combination regimens with the GAD-based diabetes vaccine Diamyd® for arresting the successive destruction of insulin-producing beta cells. Diamyd Medical licenses exclusive intellectual rights for the GAD molecule from the University of California. The company also has an exclusive license from the University of California for therapeutic use of GABA for the treatment of diabetes and other inflammation-related conditions, including metabolic syndrome and rheumatoid arthritis.

Diamyd Medical owns 46 percent of the stem cell company Cellaviva AB, which is establishing a Swedish commercial bank for private family saving of stem cells in umbilical cord blood and other sources of stem cells. Stem cells are expected to be used in Personalized Regenerative Medicine (PRM), for example, to restore beta cell mass in diabetes patients where autoimmunity has been arrested. Diamyd Medical also has a 10 percent shareholding in the medical technology company Companion Medical, Inc., based in San Diego, in the US, and a minor shareholding and other financial interests in the US gene therapy company Periphagen Holdings, Inc.

Remium Nordic AB is the Company's Certified Adviser.

For further information, please contact:

Anders Essen-Möller, Chairman Diamyd Medical AB
Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com

Diamyd Medical AB (publ)

Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.